(Boursier.com) — poxels reports on its activities and publishes its cash flow and turnover for the first quarter of 2022.
Fast Track status and Orphan Drug Designation (ODD) have been granted to PXL065 and PXL770 by the Food and Drug Administration (FDA) for the treatment of patients with adrenoleukodystrophy (ALD)
The results of the phase II study for PXL065 (DESTINY-1) in NASH are expected in the third quarter of 2022.
As of March 31, 2022, cash and cash equivalents amounted to €24 million ($26.7 million).
©2022 Boursier.com